Charles Bennett – författare

With a career that spanned from the silent era to the 1990s, British screenwriter Charles Bennett (1899--1995) lived an extraordinary life. His experiences as an actor, director, playwright, film and television writer, and novelist in both England and Hollywood left him with many amusing anecdotes, opinions about his craft, and impressions of the many famous people he knew. Among other things, Bennett was a decorated WWI hero, an eminent Shakespearean actor, and an Allied spy and propagandist during WWII, but he is best remembered for his commercially and critically acclaimed collaborations with directors Sir Alfred Hitchcock and Cecil B. DeMille.

The fruitful partnership began after Hitchcock adapted Bennett''s play Blackmail (1929) as the first British sound film. Their partnership produced six thrillers: The Man Who Knew Too Much (1934), The 39 Steps (1935), Sabotage (1936), Secret Agent (1936), Young and Innocent (1937), and Foreign Correspondent (1940). In this witty and intriguing book, Bennett discusses how their collaboration created such famous motifs as the "wrong man accused" device and the MacGuffin. He also takes readers behind the scenes with the Master of Suspense, offering his thoughts on the director''s work, sense of humor, and personal life.

Featuring an introduction and additional biographical material from Bennett''s son, editor John Charles Bennett, Hitchcock''s Partner in Suspense is a richly detailed narrative of a remarkable yet often-overlooked figure in film history.

This book offers a wide-ranging description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. The book opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention – these fines are playing an important role in changing the landscape for pharmaceutical safety.